California is currently home to 5594 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
Recruiting
This is a Phase 3, multicenter, long-term, open-label study to evaluate the safety and efficacy of once-daily orally administered deucrictibant extended-release tablet for prophylaxis to prevent angioedema attacks in participants aged ≥12 years with Hereditary Angioedema
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/23/2025
Locations: Study Site, Santa Monica, California
Conditions: Hereditary Angioedema (HAE)
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
Recruiting
The purpose of the study is to evaluate whether ibuzatrelvir is effective and safe in adults and adolescents with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible participants will be randomly assigned (by chance) to receive ibuzatrelvir or matching placebo orally for 5 days. Co-administration of locally available standard of care is allowed. The total duration of the study is around 6 months.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/23/2025
Locations: National Institute of Clinical Research - Bakersfield, Bakersfield, California
Conditions: COVID-19 SARS-CoV-2 Infection
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
Recruiting
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of once-daily orally administered deucrictibant extended-release tablet compared to placebo for prophylaxis to prevent angioedema attacks in participants aged ≥ 12 years with hereditary angioedema.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/23/2025
Locations: Study site, Santa Monica, California
Conditions: Hereditary Angioedema (HAE)
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early-stage ALS (within 2 years of ALS symptoms onset). The study comprises a core double-blind (DB) 40-week treatment period followed by an open label extension (OLE).
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/23/2025
Locations: University of California San Diego, La Jolla, California
Conditions: Amyotrophic Lateral Sclerosis (ALS)
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
Recruiting
The purpose of this study is to evaluate the efficacy and safety of rimegepant when administered during the peri-menstrual period (PMP) for intermittent prevention of migraine in women who experience menstrual migraine attacks.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
06/23/2025
Locations: Hope Clinical Research, Inc., Canoga Park, California
Conditions: Menstrual Migraine
A Study to Test Whether BI 1356225 Improves Impulsive Behavior in Men With Opioid Use Disorder Who Are Taking Buprenorphine
Recruiting
This study is open to men between 18 and 65 years of age with opioid use disorder. Opioid use disorder is also called opioid addiction or opioid dependence. People can join the study if they currently take a medicine called buprenorphine. People with opioid dependence can act on impulse, which can lead to risky behaviours. The purpose of this study is to find out whether a medicine called BI 1356225 improves impulse control in men with opioid dependence. Participants are put into 2 groups by ch... Read More
Gender:
MALE
Ages:
Between 18 years and 65 years
Trial Updated:
06/23/2025
Locations: Collaborative Neuroscience Research, LLC, Los Alamitos, Los Alamitos, California
Conditions: Opioid Use Disorder
Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of VX-993 in participants with pain associated with Diabetic Peripheral Neuropathy (DPN)
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/23/2025
Locations: Trovare Clinical Research, Bakersfield, California
Conditions: Diabetic Peripheral Neuropathic Pain
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
Recruiting
The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF. Trial website: www.aspire-ipf.com
Gender:
ALL
Ages:
40 years and above
Trial Updated:
06/23/2025
Locations: Keck Medicine of University of Southern California, Los Angeles, California
Conditions: Idiopathic Pulmonary Fibrosis (IPF)
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
Recruiting
This is a study for people with advanced cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with HER2 alterations can join the study. The purpose of this study is to find out whether a medicine called zongertinib helps people with advanced cancers with HER2 alterations. HER2 alterations can cause cancer. Zongertinib inhibits HER2. Participants are put into 13 groups based on the type of advanced cancer and the type of HER2 alterations they have.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Precision NextGen Oncology, Beverly Hills, California
Conditions: Solid Tumours
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
Recruiting
Interstitial lung disease (ILD) is a lung condition resulting in inflammation and stiffening of the lung, often associated with connective tissue diseases (CTDs). ILD causes reduction in lung volume, shortness of breath, cough and fatigue therefore has high impact on quality of life and is also the leading cause of death in participants with these conditions. The study will assess whether treatment of CTD-ILD participants with belimumab in addition to standard therapy will result in the stabiliz... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: GSK Investigational Site, Los Angeles, California
Conditions: Lung Diseases, Interstitial
eMOTION: Examining Affective Mechanisms in Physical Activity Engagement
Recruiting
This early-phase trial will test intervention strategies to influence affective mechanisms underlying physical activity and determine whether changes in those mechanisms result in change in physical activity behavior among inactive adults who are overweight or obese.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: University of Southern California, Los Angeles, California
Conditions: Physical Inactivity, Overweight or Obesity, Cancer
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
Recruiting
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy participants and in participants with moderate to severe atopic dermatitis. An additional goal is to assess the pharmacodynamics of PF-07832837 in participants with moderate to severe AD, including potential effects on clinical signs and symptoms
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/23/2025
Locations: Anaheim Clinical Trials, LLC, Anaheim, California
Conditions: Healthy Participants, Atopic Dermatitis